Biotech breakthrough has Pancreatic Cancer in its sights with new treatments
Pancreatic Cancer, ranking as the third leading cause of cancer-related deaths in Australia, grapples with a disheartening 11.5% survival rate—one of the lowest among malignancies. Compounding the issue, late-stage diagnosis and a lack of awareness regarding early signs and symptoms contribute to the grim prognosis. The available treatment options for pancreatic cancer are not only limited but also exhibit a worrying lack of efficacy.
However, a ray of hope emerges from groundbreaking biotechnological advancements that have recently surfaced. These innovations offer the potential to eradicate cancer with minimal side effects, marking a significant stride in the quest for more effective treatments.
As the world observes November as World Pancreatic Cancer Awareness Month, the spotlight falls on Johnny Quattro from VentureCrowd. He shares insights into EnGeneIC’s latest success, shedding light on the strides being made in the realm of biotechnology to combat pancreatic cancer. This promising development underscores the importance of raising awareness, fostering early detection, and advancing cutting-edge treatments to improve the outlook for those affected by this formidable disease.
Presented by VentureCrowd – To find out more about Conscious Investing, head to www.venturecrowd.com.au
